Cargando…
Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
Simultaneous inhibition of histone deacetylases (HDACs) and anaplastic lymphoma kinase (ALK) could enhance therapeutic activity against ALK addicted cancer cells. Herein, a new series of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors were designed, synthesised and evaluated. Comp...
Autores principales: | Guo, Dafeng, Yu, Yu, Long, Binyu, Deng, Ping, Ran, Dongzhi, Han, Lei, Zheng, Jiecheng, Gan, Zongjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481106/ https://www.ncbi.nlm.nih.gov/pubmed/36100230 http://dx.doi.org/10.1080/14756366.2022.2121822 |
Ejemplares similares
-
Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual
DCTN1‐ALK
and
ALK‐CLIP4
rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022) -
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016) -
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019) -
Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020) -
ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)